Latest News and Insights

Addressing the root cause of antimicrobial resistance.

Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance

2025-09-10T16:43:21-04:00

Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance Listen to the podcast here. Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is [...]

Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance2025-09-10T16:43:21-04:00

How Innovation is Turning the Tide in the Costly Fight Against Antimicrobial Resistance

2025-09-08T12:09:09-04:00

A century ago, antibiotics transformed medicine. What were once deadly infections suddenly became curable, ushering in an era where surgery, childbirth, and even everyday cuts carried far less risk. Unfortunately, that medical miracle is now under threat. Across the world, doctors and healthcare systems are [...]

How Innovation is Turning the Tide in the Costly Fight Against Antimicrobial Resistance2025-09-08T12:09:09-04:00

Smart Investing in Antimicrobial Resistance Solutions Disrupts Biotech Market

2025-09-08T12:03:44-04:00

Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.

Smart Investing in Antimicrobial Resistance Solutions Disrupts Biotech Market2025-09-08T12:03:44-04:00

Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance

2025-07-24T17:04:14-04:00

Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.

Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance2025-07-24T17:04:14-04:00

Turning the Tide: Innovations in the Fight Against Super Gonorrhea

2025-07-24T16:52:07-04:00

As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.

Turning the Tide: Innovations in the Fight Against Super Gonorrhea2025-07-24T16:52:07-04:00

Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea

2025-07-27T13:33:18-04:00

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.

Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea2025-07-27T13:33:18-04:00

$2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea

2025-07-15T21:51:38-04:00

TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.

$2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea2025-07-15T21:51:38-04:00

Innovative Approaches to Antibiotic Resistance: The Promise of TXA709

2024-12-17T13:07:27-05:00

Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.

Innovative Approaches to Antibiotic Resistance: The Promise of TXA7092024-12-17T13:07:27-05:00
Go to Top